Group One Trading
TERN

Group One Trading’s Terns Pharmaceuticals TERN Stock Holding History

Group One Trading’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.8M Buy
602,400
+410,500
+214% +$16.9M 0.06% 313
2025
Q4 		$7.75M Buy
191,900
+129,300
+207% +$2.99M 0.01% 1127
2025
Q3 		$470K Buy
62,600
+32,900
+111% +$210K ﹤0.01% 3773
2025
Q2 		$111K Sell
29,700
-21,500
-42% -$67.1K ﹤0.01% 4884
2025
Q1 		$141K Sell
51,200
-99,800
-66% -$408K ﹤0.01% 4310
2024
Q4 		$837K Sell
151,000
-28,900
-16% -$196K ﹤0.01% 2735
2024
Q3 		$1.5M Buy
179,900
+90,800
+102% +$747K ﹤0.01% 1965
2024
Q2 		$607K Buy
89,100
+81,800
+1,121% +$496K ﹤0.01% 2386
2024
Q1 		$47.9K Sell
7,300
-54,000
-88% -$353K ﹤0.01% 4757
2023
Q4 		$398K Sell
61,300
-22,200
-27% -$117K ﹤0.01% 3261
2023
Q3 		$420K Buy
83,500
+26,100
+45% +$166K ﹤0.01% 3083
2023
Q2 		$502K Buy
+57,400
New +$669K ﹤0.01% 3014

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Group One Trading's TERN Position: Q1 2026 in Review

Group One Trading sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 70,844 shares — an estimated $2.91M sold.

Group One Trading first reported a position in TERN in Q3 2025 and held it in 2 quarters. The position peaked at $2.86M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Group One Trading reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 70,844 Terns Pharmaceuticals shares in Q1 2026, an estimated $2.91M.
  • Group One Trading first reported a position in Terns Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Group One Trading's Terns Pharmaceuticals position peaked at $2.86M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.